医药行业分析
- (2024-11-19)
- (2024-11-19)
- (2024-11-19)
- (2024-11-19)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-18)
- (2024-11-17)
- (2024-11-17)
JAMA子刊:睡觉腿抽筋,维生素K2或能防!成都市第三人民医院团队发现,八周维生素K2治疗可安全有效管理老年人夜间下肢痛性痉挛
(2024-11-17)- (2024-11-17)
- (2024-11-16)
- (2024-11-15)
- (2024-11-15)
- (2024-11-15)
- (2024-11-15)
- (2024-11-15)
- (2024-11-15)
- (2024-11-15)
- (2024-11-15)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-14)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-13)
- (2024-11-12)
- (2024-11-12)
- (2024-11-12)
- (2024-11-12)
- (2024-11-12)
天演药业于2024 SITC年会上公布其抗 CTLA-4 SAFEbody® ADG126(Muzastotug)单一疗法及与抗 PD-1 疗法联用最新临床数据
(2024-11-12)- (2024-11-12)
- (2024-11-12)
百奥赛图宣布IDEAYA提名具有同类首创潜力的B7H3/PTK7双特异性ADC(IDE034)作为开发候选药物并行使选择权
(2024-11-12)- (2024-11-11)
- (2024-11-11)
- (2024-11-11)